Rosetta Genomics to Raise $4.5M Through Direct Offering

The microRNA-based molecular diagnostics developer plans to use earnings from the sale of securities for a range of corporate purposes.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.